Evidence Summary
Evidence Level: Preliminary
Mechanism: Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Leukotriene antagonist (10mg daily) for MCAS/inflammatory overlap. Supported by MCAS obs + urticaria RCTs. Low-risk add-on.